Compare GROY & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GROY | VALN |
|---|---|---|
| Founded | 2020 | 2012 |
| Country | Canada | France |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 938.2M | 855.8M |
| IPO Year | 2021 | 2021 |
| Metric | GROY | VALN |
|---|---|---|
| Price | $4.94 | $9.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $5.15 | ★ $15.75 |
| AVG Volume (30 Days) | ★ 3.0M | 23.8K |
| Earning Date | 11-05-2025 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $14,464,000.00 | ★ $211,089,992.00 |
| Revenue This Year | $72.11 | $3.64 |
| Revenue Next Year | $100.63 | $12.23 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 86.30 | 13.48 |
| 52 Week Low | $1.20 | $4.22 |
| 52 Week High | $5.05 | $12.25 |
| Indicator | GROY | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 75.93 | 62.96 |
| Support Level | $4.16 | $9.85 |
| Resistance Level | $4.45 | $10.37 |
| Average True Range (ATR) | 0.19 | 0.34 |
| MACD | 0.07 | 0.13 |
| Stochastic Oscillator | 90.54 | 87.83 |
Gold Royalty Corp is a precious metals-focused royalty and mineral streaming company. The company offers creative financing solutions to the metals and mining industry. The company's mission is to acquire royalties, streams and similar interests at varying stages of the mine life cycle to build a balanced portfolio offering near, medium and longer-term attractive returns for investors. It has its business as a single operating segment, being the investment in royalty and mineral stream interests. The company derives maximum revenue from Canada.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.